Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma

Autor:	Andrew Gnan, John M. Kirkwood, Yan Lin, Chelsea Pruckner, Uma N. M. Rao, Zahra Rahman, Amy Rose, James F. Pingpank, Melissa Wilson, Hussein Abdul-Hassan Tawbi, Robert L. Ferris, Priyanka Vallabhaneni, Matthew P. Holtzman, Amanda McFadden, Ahmad A. Tarhini
Rok vydání:	2016
Předmět:	0301 basic medicine Oncology Cancer Research medicine.medical_specialty business.industry Ipilimumab 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Recurrent Melanoma hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine medicine Combination immunotherapy business medicine.drug Advanced melanoma
Zdroj:	Journal of Clinical Oncology. 34:9585-9585
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2016.34.15_suppl.9585
Popis:	9585Background: Neoadjuvant ipilimumab (ipi) at 3 or 10 mg/kg in combination with high dose IFNα2b (HDI) for locally/regionally advanced or recurrent melanoma may improve the clinical outcomes of t...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c8f9c077decafc7308597a1785f196f1 https://doi.org/10.1200/jco.2016.34.15_suppl.9585 Zobrazit plný text záznamu